臨床研究等提出・公開システム

A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 in participants with metastatic or unresectable solid tumors with HER2-activating mutations (panSOHO)

A Phase 2 basket study of BAY 2927088 in participants with metastatic or unresectable solid tumors with HER2-activating mutations by Bayer Yakuhin, Ltd. (panSOHO)

Myoishi Masafumi

Bayer Yakuhin, Ltd.

2-4-9 Umeda, Kita-ku, Osaka, Osaka

byl_ct_contact@bayer.com

Dedicated contact

Bayer Yakuhin, Ltd.

2-4-9 Umeda, Kita-ku, Osaka, Osaka

+81-6-6133-6363

byl_ct_contact@bayer.com

Recruiting

Feb. 25, 2025

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; breast cancer and other solid tumor cancer, excluding NSCLC)
2. Participant must be >= 18 years of age or over the legal age of consent
3. Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments
4. Documented activating HER2 mutation
5. At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria

1. Primary diagnosis of non-small cell lung cancer (NSCLC)
2. Prior treatment with a HER2 tyrosine kinase inhibitor (TKI)
3. Active brain metastases
4. Uncontrolled, severe, intercurrent illness

Both

Metastatic or unresectable locally advanced solid tumors with HER2-activating mutations

Sevabertinib (BAY2927088) tablet, oral

- Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR

- Duration of response (DOR) per RECIST 1.1 as assessed by BICR
- Time to response (TTR) per RECIST 1.1 as assessed by BICR
- ORR per RECIST 1.1 as assessed by the investigator
- Disease control rate (DCR) per RECIST 1.1 as assessed by BICR
- DCR 12 weeks per RECIST 1.1 as assessed by BICR
- Progression-free survival (PFS) per RECIST 1.1 as assessed by BICR
- Disease control rate (DCR) per RECIST 1.1 as assessed by the investigator
- DCR >=12 weeks per RECIST 1.1 as assessed by the investigator
- Progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator
- DOR per RECIST 1.1 as assessed by the investigator
- TTR per RECIST 1.1 as assessed by the investigator
- Overall survival (OS)
- Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) per CTCAE v 5.0, categorized by severity, including number of participants who discontinue study treatment due to an AE
- Time to deterioration in EORTC QLQ-C30 physical functioning domain score
- Change from baseline in EORTC QLQ-C30 physical functioning domain score
- Change from baseline in EORTC QLQ-C30 global health status/quality of life (QoL)

+81-11-706-7061

Jan. 21, 2025

No

Australia/Canada/China/Denmark/Spain/France/Italy/South Korea/United States